Predict the Risk of Prostate Cancer at Re-Biopsy
The PINgenius™ Test allows patients to prepare for the future by
knowing their risk. Developed by our pathology laboratory services team
at Inform Diagnostics, this new test helps treating physicians predict
the risk of prostate cancer at re-biopsy for patients with high-grade
prostatic intraepithelial neoplasia (HGPIN).
The results of the PINgenius™ Test allow medical professionals to
answer questions such as:
- Which HGPIN patients need re-biopsy?
- Which HGPIN patients need conservative follow-up?
Histological Risk Factors
Inform Diagnostics independent research suggests a high-risk (≈60%) of discovering
prostate cancer upon re-biopsy when testing positive for PINgenius, combined
with certain histological risk factors:
- High-grade prostatic intraepithelial neoplasia (HGPIN) is a putative precursor
lesion to prostate cancer
- Men with an isolated HGPIN diagnosis from a prostate biopsy are at risk
of harboring or developing prostate cancer at repeat biopsy
- Existing clinical and pathological risk-assessment tools have not accurately
and consistently identified which patients should be conservatively followed
and which patients will need a repeat biopsy
- The PINgenius test employs biomarker overexpression as well as several
histological factors to help gauge the risk of prostate cancer at repeat biopsy.
The following are recommendations based on various PINgenius results:
- If PINgenius result suggests HIGH RISK—Repeat biopsy may be indicated.
- If PINgenius result suggests LOW RISK—Conservative follow up may
be indicated; delay or avoid re-biopsy unless other clinical parameters
*NOTE: The timeframe to schedule re-biopsy is a decision made between the
clinician and patient.
Learn more about the PINgenius Test
contact us with your questions about the PINgenius test. We can connect you to a member of our Sales
or Pathology teams.
Additional recommended reading:
- Park K et al. TMPRSS2: ERG Gene Fusion Predicts Subsequent Detection of
Prostate Cancer in Patients with High-grade Prostatic Intraepithelial
Neoplasia. Journal of Clin Oncology, 2013
- Shah RB. Clinical Application of Novel ERG immunohistochemistry in Prostate
Cancer Diagnosis and Management. Review. Adv Anat Pathol, 20(2): 117–24, 2013
- Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate
cancer: clonal progression of ERG-positive tumor cells and potential for
ERG-based stratification. Prostate Cancer Prostatic Dis 2010;13:228–37.